SH
Soren Hostrup
About Soren Hostrup
Data last updated:
Soren Hostrup is a Director at Xellia Pharmaceuticals Private Limited (since 2024). The company operates in Business Services. Xellia Pharmaceuticals Private Limited reported revenue of ₹28.32 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 20 Aug 2024 | 2010 | ₹28.32 Cr (FY 2025) | Active |
Board colleagues of Soren Hostrup
| Name | DIN | Company | Designation |
|---|---|---|---|
| Eva Blem | 11469480 | Xellia Pharmaceuticals Private Limited | Additional Director |
| Kasi Visweswara Venkata Satya Lakshmi Nagakishore Sripada | 11416360 | Xellia Pharmaceuticals Private Limited | Additional Director |
| Per Bork Eppers | 11469479 | Xellia Pharmaceuticals Private Limited | Additional Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Soren Hostrup
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Soren Hostrup
Soren Hostrup currently holds 1 directorship: Xellia Pharmaceuticals Private Limited (Director, since 20 Aug 2024, revenue ₹28.32 Cr (FY 2025)).
Soren Hostrup was first appointed on 20 Aug 2024 as Director at Xellia Pharmaceuticals Private Limited.
The current boards of Soren Hostrup's companies include Eva Blem (Xellia Pharmaceuticals Private Limited), Kasi Visweswara Venkata Satya Lakshmi Nagakishore Sripada (Xellia Pharmaceuticals Private Limited), Per Bork Eppers (Xellia Pharmaceuticals Private Limited).